Subsequent to the recommendation for regulatory approval under the European decentralized procedure, Basilea received the marketing authorization for Toctino in Belgium and Luxemburg.
Following the regulatory approval of Toctino in Belgium and Luxemburg, Basilea will submit a pricing and reimbursement dossier to the country authorities. Toctino was developed by Basilea Pharmaceutica International.